Skip Navigation


JAC Advance Access originally published online on August 26, 2005
Journal of Antimicrobial Chemotherapy 2005 56(4):793-794; doi:10.1093/jac/dki290
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/4/793    most recent
dki290v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Twagira, M. F. N.
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twagira, M. F. N.
Right arrow Articles by Smith, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Development of a real-time PCR assay on the Roche Light-Cycler for the detection of erm and mef erythromycin resistance genes in ß-haemolytic streptococci

M. F. N. Twagira1, J. J. Wade1, I. Eltringham1 and M. Smith2,*

1 Department of Microbiology, Health Protection Agency London, King's College Hospital, Denmark Hill, London SE5 9RS, UK; 2 South London Specialist Virology Centre, Health Protection Agency London, King's College Hospital (Dulwich Site), London SE22 8QF, UK

* Corresponding author. Tel: +44-20-8693-3005; Fax: +44-20-7346-6477; E-mail: Melvyn.Smith@kingsch.nhs.uk

Keywords: PCR , erythromycin , Streptococcus spp.

The first 10% of the full text of this article appears below.

Sir,

Although erythromycin resistance in streptococci is predominantly due to target site modification by rRNA methylases (encoded by erm genes) or drug efflux (encoded by mef genes), novel resistance mechanisms continue to emerge.1 Furthermore, susceptibility to macrolides, lincosamides, streptogramins and ketolides varies depending on the distribution of different erythromycin resistance mechanisms.1 Therefore, phenotypic and genotypic erythromycin resistance surveillance data are required as an adjunct in determining therapy for streptococcal infections. In the UK, erythromycin resistance in Lancefield group B (GBS), C (GCS) and G (GGS) streptococci is increasing, but data on . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?